(Q42252352)

English

Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study

scientific article published on 28 November 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

multicenter clinical trial

0 references

0 references

9

object named as

Takashi Kumada

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Hidenori Toyoda

2

object named as

Hidenori Toyoda

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Koichi Takaguchi

5

object named as

Koichi Takaguchi

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Noritomo Shimada

1

object named as

Noritomo Shimada

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

6

object named as

Keizo Kato

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Akihito Tsubota

3

object named as

Akihito Tsubota

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

10

object named as

Michio Sata

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Kazuhiro Matsuyama

8

object named as

Kazuhiro Matsuyama

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

author name string

Tatsuya Ide

4

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Masaki Kondoh

7

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

publication date

28 November 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

49

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1485-1494

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Telaprevir for previously treated chronic HCV infection

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

IL28B in the era of direct-acting antivirals for hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Response-guided telaprevir combination treatment for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Evolutionary analysis of variants of hepatitis C virus found in South-East Asia: comparison with classifications based upon sequence similarity.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0918-7

21 January 2018

α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype

1 reference

https://pubmed.ncbi.nlm.nih.gov/24287582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24287582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24287582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/24287582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00535-013-0918-7

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42252352&oldid=1940148517"